Published in Cancer Genet Cytogenet on April 01, 2005
Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer (2011) 1.24
Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int J Cancer (2008) 1.21
Molecular profiling of cervical cancer progression. Br J Cancer (2007) 1.07
Regulatory functions of Nm23-H2 in tumorigenesis: insights from biochemical to clinical perspectives. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Molecular fixative enables expression microarray analysis of microdissected clinical cervical specimens. Exp Mol Pathol (2014) 0.75
Genetic dysregulation in recurrent respiratory papillomatosis. Laryngoscope (2014) 0.75
More precise prediction in Chinese patients with penile squamous cell carcinoma: protein kinase CK2α catalytic subunit (CK2α) as a poor prognosticator. Oncotarget (2017) 0.75
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res (2002) 2.57
Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res (2004) 2.36
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst (2007) 2.34
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol (2009) 1.90
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg (2004) 1.72
Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat (2007) 1.54
Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol (2013) 1.52
Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns. Reprod Sci (2007) 1.43
Detection of hepatitis C virus (HCV) RNA in normal cervical smears of HCV-seropositive patients. Clin Infect Dis (2002) 1.42
Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast. Am J Pathol (2006) 1.41
Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol (2004) 1.40
Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene (2002) 1.35
Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat (2003) 1.29
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol (2008) 1.28
Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res (2006) 1.24
A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res (2012) 1.21
Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res (2003) 1.16
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol (2007) 1.14
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res (2008) 1.11
MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat (2002) 1.10
Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2012) 1.10
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. Ann Surg (2003) 1.06
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer (2006) 1.05
Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer. Clin Exp Metastasis (2006) 1.01
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol (2007) 1.00
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol (2005) 0.98
Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand (2004) 0.98
Preoperative core needle biopsy as an independent risk factor for wound infection after breast surgery. Obstet Gynecol (2003) 0.98
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat (2007) 0.97
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol (2003) 0.97
Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clin Cancer Res (2004) 0.96
Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics (2006) 0.95
Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiother Oncol (2002) 0.95
EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR. Oncol Rep (2005) 0.94
European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol (2004) 0.93
Factors predicting severe perineal trauma during childbirth: role of forceps delivery routinely combined with mediolateral episiotomy. Am J Obstet Gynecol (2005) 0.92
Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res (2003) 0.91
Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur J Cancer (2005) 0.91
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers. Hum Mutat (2005) 0.90
Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers. Breast Cancer Res Treat (2003) 0.89
Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol (2005) 0.89
Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat (2002) 0.89
Survival of women with breast cancer in Austria by age, stage and period of diagnosis. Wien Klin Wochenschr (2002) 0.88
Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril (2004) 0.88
Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women. Breast Cancer Res Treat (2002) 0.88
Genetic alterations in endometrial hyperplasia and cancer. Cancer Lett (2002) 0.87
Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep (2006) 0.87
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res (2009) 0.87
The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. Oncol Rep (2003) 0.86
Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig (2004) 0.86
Gene expression profiling of cervical tissue during physiological cervical effacement. Obstet Gynecol (2005) 0.86
Prevalence of cervical and intrauterine human papillomavirus infection in the third trimester in asymptomatic women. J Soc Gynecol Investig (2005) 0.86
Malignant fibrous histiocytoma (MFH) of the mesentery: a case report. Anticancer Res (2002) 0.86
Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat (2004) 0.85
Extracellular matrix proteins influence phenotype and cytokine expression in human breast cancer cell lines. Eur Cytokine Netw (2002) 0.85
Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer. Oncol Rep (2007) 0.84
Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis. Fertil Steril (2005) 0.84
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer (2004) 0.84
Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis? J Cancer Res Clin Oncol (2008) 0.84
High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting. Int J Cancer (2014) 0.84
Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol (2005) 0.83
Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study. Gynecol Oncol (2006) 0.82
The validity of complex breast cysts after surgery. Am J Surg (2008) 0.82
Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study. J Reprod Med (2003) 0.81
Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers. Eur J Cancer Prev (2012) 0.80
Expression of the human MTA1 gene in breast cell lines and in breast cancer tissues. Oncol Res (2007) 0.80
Clinicopathologic profile of gestational trophoblastic disease. Wien Klin Wochenschr (2003) 0.80
beta-HCG/LH receptor (beta-HCG/LH-R) expression in eutopic endometrium and endometriotic implants: evidence for beta-HCG sensitivity of endometriosis. Reprod Sci (2008) 0.80
Impact of AdipoR1 expression on breast cancer development. Gynecol Oncol (2010) 0.80